<DOC>
	<DOCNO>NCT00988195</DOCNO>
	<brief_summary>The purpose study determine whether recombinant human arginase ( PEG-BCT-100 ) safe effective treatment advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Study Pegylated Human Recombinant Arginase Liver Cancer</brief_title>
	<detailed_description>The primary objective study : - To establish safe dose level weekly intravenous administration PEG- BCT-100 ( rhArgIpeg5000 ) base clinical laboratory safety assessment follow range dos ( 500 &gt; 5000 U/kg ) . - To define optimal biological dose ( OBD ) PEG-BCT-100 base pharmacodynamics ( PD ) arginine depletion ( ADD ) relative plasma PK PEG- BCT-100 . - To evaluate objective tumor response PEG-BCT-100 HCC patient receive weekly dos PEG-BCT-100 alone combination standard dose doxorubicin Secondary objective study : - To define toxicity associate metabolic cellular alteration ADD relative dose PK PEG-BCT-100 ( rhArgIpeg5000 ) . - To develop safe biologically active dose schedule PEG-BCT-100 treatment phase 2 trial , either monotherapy combination best standard care chemotherapy . - To confirm safety initial anti-tumor activity prefer dose regimen PEG-BCT-100 18 additional patient advance HCC</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Confirmed diagnosis HCC accord European Association Study Liver criterion Known underlie HCC etiology specify hepatitis B , hepatitis C , post alcoholic cirrhosis , HCC lesion ( ) resectable measurable CT scan Progression nonresponse HCC lesions treatment consider best standard care surgical resection , radiofrequency ablation , chemoembolization No cancer treatment surgery within prior 4 week , either chemotherapy , target biologic enzyme , either approve investigational ; Males females 18 75 yearsold , inclusive ; Ability willingness provide write informed consent ; Karnofsky performance status 80 % expect survival 12 week ; , Negative urine pregnancy test , female , willingness use effective method contraception entire study period Advancing liver failure indicate uncontrolled ascites , pleural effusion , encephalopathy , ChildPugh score C Significant hepatic , renal bone marrow dysfunction indicate total bilirubin &gt; 40 Âµmol/L , evidence bile duct obstruction , serum albumin &lt; 30 g/L , serum SGOT &gt; 5 x upper limit normal , ANC &lt; 1.0 x 10^9/L , platelet &lt; 100 x 10^9/L , INR &gt; 2.0 Significant cardiac pulmonary disease define New York Heart Association ( NYHA ) Class III IV , VEF &lt; 50 % echo MUGA , history myocardial infarction within past 6 month , significant unstable arrhythmia evidence ischemia ECG Pregnant nursing woman . NOTE : Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Significant active infection include HIV require oral parenteral antiinfective therapy ; Use investigational drug ( ) within 4 week enrollment ; , Prior treatment arginine deplete agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Neoplasm</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
</DOC>